KIMS plans ₹1,500 cr QIP as profit slides 69% on expansion drag
Revenue grew 35% to ₹1,084 cr, but new units in Bangalore, Thane, and Nasik burned ₹32 cr in EBITDA this quarter.
What's new
- Board approved a ₹1,500 cr QIP to trim a debt pile exceeding ₹3,000 cr.
- New hospitals contributed ₹224 cr in revenue but posted an aggregate EBITDA loss of ₹32 cr.
- Management targets break-even for new units within 12-18 months, pending insurance approvals.
Why it matters
The company is in an aggressive growth phase where revenue gains are currently eclipsed by the high cost of new hospital ramp-ups. The QIP is a necessary move to reset a balance sheet carrying over ₹3,000 crore in debt as the firm builds out its footprint across five states.
What we're watching
- Timeline and pricing of the ₹1,500 cr QIP.
- Progress on insurance empanelment for the Bangalore, Thane, and Nasik units.
- Whether EBITDA margins can recover from their current 19.9% level.
The full read
Krishna Institute of Medical Sciences (KIMS) finished Q4 FY26 with a stark disconnect between top-line growth and bottom-line health. While revenue climbed 35% to ₹1,084 crore, profit plunged 69% to ₹33 crore as the company absorbed an EBITDA loss of ₹32 crore from its recently opened hospitals in Bangalore, Thane, and Nasik. These new units represent a significant drag on margins, which slipped to 19.9% this quarter. To clear the runway for expansion into Karnataka, Kerala, Tamil Nadu, Andhra Pradesh, and Telangana, KIMS is tapping the market for a ₹1,500 crore QIP. The priority is to deleverage a balance sheet burdened by over ₹3,000 crore in debt. Management expects the new hospitals to turn profitable within 12-18 months, though success hinges entirely on securing insurance empanelment. Until those approvals land, the high overheads of the expansion strategy will continue to weigh on the company's profitability.